Wedbush initiated coverage of Larimar Therapeutics with an Outperform rating and $22 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LRMR:
- Larimar Therapeutics initiated with a Buy at H.C. Wainwright
- Larimar Therapeutics initiated with a Buy at JonesResearch
- Larimar Therapeutics initiated with an Outperform at Baird
- Larimar Therapeutics sees cash runway into 2026
- Larimar Therapeutics plans PK run-in study in adolescents, children with FA